Pathways leading to Alzheimer’s Disease
Speaker: Maria L. Maccecchini
June 2009, World Pharma Congress on Alzheimer’s Disease
The deterioration of cognitive function in Alzheimer’s disease (AD) is not due to a single mechanism or gene, but to a large number of interrelated pathways.
QR Pharma is developing a compound, Posiphen®, which inhibits APP levels. When we started working with Posiphen® the understanding was that APP is the precursor to Aß and, therefore, lowers Aß and amyloid plaque accumulation. Additional research showed that APP is also a precursor to N-APP which causes neuronal cell death. Furthermore, Aß enhances the hyperphosphorylation of tau, which leads to self assembly and the formation of neurofibrillary tangles (NTFs). So inhibition of APP lowers levels of Aß leading to less senile plaques, lowers levels of N-APP leading to nerve cell preservation and lowers levels of hyperphosphorylated tau leading to lower NTF load.